Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus in Ovarian Cancer with CA125 Only Relapse
NCT00926107Phase 2Terminated
- Sponsor
- HeCOG
- Start
- Jun 2009
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in ovarian cancer, sponsored by HeCOG. Primary endpoint: Clinical Progression Free Survival at 6 months. Started Jun 2009; status: terminated.
02
Drugs
temsirolimus
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00926107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00926107.